1996 Fiscal Year Final Research Report Summary
Expanded polytetrafluoroethelene graft precoated with basic fibroblast growth factor
| Project/Area Number |
06671196
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
SAKURAI Tsunehisa Nagoya University・School of Medicine Associate Professor, 医学部, 助教授 (50144142)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIKIMI Naomichi Nagoya University・School of Medicine Assistant Professor, 医学部, 講師 (40242862)
|
|---|
| Project Period (FY) |
1994 – 1996
|
| Keywords | bFGF / ePTFE / sustained release |
|---|
| Research Abstract |
This study was designed to make an expanded polytetra-fluoro-ethylene (ePTFE) graft with sustained release of recobinant basic fibroblast growth factor (bFGF) and to evaluate the effect of this graft on luminal endothelialization. ePTFE grafts with an internal diameter of 3 mm and internodal distance of 30 mm were soaked with recombinant bFGF solution under a certain pressure and freeze-dried. To control the release rate of bFGF,biodegradable hydroxypropylchitosan acetate (HPCHA) was incorporated into the graft with bFGF.HPPCHA was dissolved in bFGF solution (180 mg/ml) in a concentration of 4% (w/v). In an in vivo study where the ePTFE disks with/without bFGF were implanted in rabbit skin pockets, almost 100% of bFGF from HPCHA-free disks was released within 24 hours, while some 60% remained after 24 hours in the HPCHA-loaded disks.
In animal experiment, nonreinforced ePTFE grafts, 5 mm in diameter, 30mm internodal-distance, incorporated with/without recobinant bFGF and HPCHA were implanted between femoral arteries and veins of 10 mongrel dogs. Grafts were explanted after 8 weeks and stained with hematoxilin and eosine for light microscopy. At 8 weeks after operation, 8 out of 10 grafts incorporated with recobinant bFGF and HPCHA were patent, while 6 out of 10 grafts without bFGF were patent. Microscopically, 7 of 8 patent explants in FGF loaded grafts and three of six patent explants in FGF free grafts revealed endothelialized luminal surface.
To conclude, HPCHA is useful as a biodegradable carrier for controlled release of bFGF.bFGF is supposed to promote the luminal endothelialization and the healing of ePTFE grafts.
|
